Please login to the form below
KRAS mutation
This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.
Routine gene test could guide use of cancer chemotherapy, new study shows
Separate data from a clinical trial showed that patients with another mutation in the KRAS gene called KRASG13 – 8% of those in the study – saw their median survival triple with the ... treatment. For those without KRAS mutations, survival was found
Latest news
-
Amgen announces positive results for Lumakras colorectal cancer combination treatment
KRAS mutations are among the most common genetic alterations in colorectal cancers, with the KRAS G12C mutation present in approximately 3-5% of colorectal cancers. ... In total, 40 patients with heavily pre-treated KRAS G12C-mutated chemo-refractory
-
Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer
KRAS G12C is the most common KRAS mutation in NSCLC, with around 13% of patients with NSCLC harbouring the KRAS G12C mutation. ... Treatment options are limited for NSCLC patients with the KRAS G12C mutation whose first-line treatment has failed to work
-
NICE recommends Amgen’s Lumykras for non-small-cell lung cancer
It will be available as an option for adult patients diagnosed with the KRAS G12C mutation-positive locally advanced, or metastatic non-small-cell lung cancer (NSCLC) patients, whose disease has ... lung cancers and approximately 13% of these are
-
Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer
The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation. ... It is estimated that approximately 90% of patients living with pancreatic cancer carry a KRAS mutation,
-
Amgen’s Lumykras receives conditional marketing authorisation from EC
The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation. ... To date, the trial is the largest conducted for patients diagnosed with the KRAS G12C mutation.
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
Interview: AstraZeneca's Susan Galbraith
This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
